NORIS MEDICAL LTD. – Trademark Portfolio

Entity Type: 99

NORIS MEDICAL LTD. holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 11 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 2 Nice Classification classes. Currently, 7 trademarks are registered and 6 are pending. Notable registered marks include ZYGO, EZGOMA, LONGY-N, ZYGO PRO, and ZYGOMANIA.

8 Hataasia Street

3688808 Nesher

17 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

NORIS MEDICAL LTD.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (11 filings)

Surgical, medical, dental and veterinary apparatus and instruments

41
Education & Entertainment (9 filings)

Education; providing of training; entertainment; sporting and cultural activities

Frequently Asked Questions

How many trademarks does NORIS MEDICAL LTD. have?

NORIS MEDICAL LTD. has 17 U.S. trademarks filed with the USPTO. Of these, 7 registered, 6 pending, 4 abandoned.

What trademark classes does NORIS MEDICAL LTD. file in?

NORIS MEDICAL LTD. files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 41 (Education & Entertainment). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are NORIS MEDICAL LTD.'s most well-known trademarks?

NORIS MEDICAL LTD.'s registered trademark portfolio includes well-known marks such as ZYGO, EZGOMA, LONGY-N, ZYGO PRO, and ZYGOMANIA. These are among 7 currently registered trademarks in the portfolio.

What is NORIS MEDICAL LTD.'s trademark registration success rate?

NORIS MEDICAL LTD. has a 64% trademark registration rate, with 7 out of 11 resolved applications resulting in successful registration. Currently, 6 applications are pending review.